These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21351287)

  • 1. Extended model-based designs for more complex dose-finding studies.
    O'Quigley J; Conaway M
    Stat Med; 2011 Jul; 30(17):2062-9. PubMed ID: 21351287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I design for completely or partially ordered treatment schedules.
    Wages NA; O'Quigley J; Conaway MR
    Stat Med; 2014 Feb; 33(4):569-79. PubMed ID: 24114957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continual reassessment and related designs in dose-finding studies.
    Iasonos A; O'Quigley J
    Stat Med; 2011 Jul; 30(17):2057-61. PubMed ID: 21351292
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The continual reassessment method for dose-finding studies: a tutorial.
    Garrett-Mayer E
    Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of two phase I trial designs.
    Korn EL; Midthune D; Chen TT; Rubinstein LV; Christian MC; Simon RM
    Stat Med; 1994 Sep; 13(18):1799-806. PubMed ID: 7997713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The continual reassessment method in cancer phase I clinical trials: a simulation study.
    Chevret S
    Stat Med; 1993 Jun; 12(12):1093-108. PubMed ID: 8210815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the relative conservativeness of Bayesian logistic regression method in oncology dose-finding studies.
    Yang CH; Cheng G; Lin R
    Pharm Stat; 2024; 23(4):585-594. PubMed ID: 38317370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical aspects of the Bayesian approach to phase I cancer trials.
    Neuenschwander B; Branson M; Gsponer T
    Stat Med; 2008 Jun; 27(13):2420-39. PubMed ID: 18344187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.
    Asakawa T; Hirakawa A; Hamada C
    J Biopharm Stat; 2014; 24(2):310-25. PubMed ID: 24605971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.
    Takeda K; Morita S
    Pharm Stat; 2018 Jul; 17(4):372-382. PubMed ID: 29372582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.